Exact Mass: 521.2705

Exact Mass Matches: 521.2705

Found 500 metabolites which its exact mass value is equals to given mass value 521.2705, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Morphiceptin

(2S)-1-[(2S)-2-({[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-phenylpropanoyl]pyrrolidine-2-carboximidate

C28H35N5O5 (521.2638)

D002491 - Central Nervous System Agents > D000697 - Central Nervous System Stimulants > D003292 - Convulsants D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D018377 - Neurotransmitter Agents > D018847 - Opioid Peptides Morphiceptin is a peptide isolated from beta-casein. [HMDB] D018377 - Neurotransmitter Agents > D004723 - Endorphins Morphiceptin is a peptide isolated from beta-casein. Morphiceptin is a potent and specific agonist for morphine (μ) receptors. Morphiceptin, as a synthetic peptide, is the amide of a fragment of the milk protein β-casein. Morphiceptin has morphinelike activities and is highly specific for morphine (μ) receptors but not for enkephalin (?) receptors[1]. Morphiceptin is a potent and specific agonist for morphine (μ) receptors. Morphiceptin, as a synthetic peptide, is the amide of a fragment of the milk protein β-casein. Morphiceptin has morphinelike activities and is highly specific for morphine (μ) receptors but not for enkephalin (?) receptors[1].

LysoPS(18:2(9Z,12Z)/0:0)

(2S)-2-amino-3-{[hydroxy((2R)-2-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoyloxy]propoxy)phosphoryl]oxy}propanoic acid

C24H44NO9P (521.2754)

LysoPS(18:2(9Z,12Z)/0:0) is a lysophosphatidylserine. It is a glycerophospholipid in which a phosphorylserine moiety occupies a glycerol substitution site. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic. However, it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Lysophosphatidylserines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. LysoPS(18:2(9Z,12Z)/0:0), in particular, consists of one chain of linoleic acid at the C-1 position.

Batrachotoxinin A 20-alpha-benzoate

1-{9,12-dihydroxy-6,16-dimethyl-10,19-dioxa-16-azahexacyclo[12.5.3.1^{5,9}.0^{1,14}.0^{2,11}.0^{6,11}]tricosa-2,21-dien-22-yl}ethyl benzoate

C31H39NO6 (521.2777)

D009676 - Noxae > D011042 - Poisons > D014688 - Venoms

Thienorphine

3-(cyclopropylmethyl)-16-[2-hydroxy-4-(thiophen-2-yl)butan-2-yl]-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1^{2,8}.0^{1,6}.0^{6,14}.0^{7,12}]icosa-7,9,11-trien-11-ol

C31H39NO4S (521.26)

D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids

Epothilone B10

C28H43NO6S (521.2811)

Merresectine D beta-D-glucoside

C27H39NO9 (521.2625)

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]-4-carbamoylbutanamido]-3-methylpentanoic acid

C25H39N5O7 (521.2849)

Tyr Val Gln Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]-4-carbamoylbutanamido]-4-methylpentanoic acid

C25H39N5O7 (521.2849)

Deproceptin

L-Tyrosyl-L-prolyl-L-phenylalanyl-L-prolinamide

C28H35N5O5 (521.2638)

Morphiceptin is a potent and specific agonist for morphine (μ) receptors. Morphiceptin, as a synthetic peptide, is the amide of a fragment of the milk protein β-casein. Morphiceptin has morphinelike activities and is highly specific for morphine (μ) receptors but not for enkephalin (?) receptors[1]. Morphiceptin is a potent and specific agonist for morphine (μ) receptors. Morphiceptin, as a synthetic peptide, is the amide of a fragment of the milk protein β-casein. Morphiceptin has morphinelike activities and is highly specific for morphine (μ) receptors but not for enkephalin (?) receptors[1].

PS(18:2(9Z,12Z)/0:0)

1-(9Z,12Z-octadecadienoyl)-glycero-3-phosphoserine

C24H44NO9P (521.2754)

LPS 18:2

1-(9Z,12Z-octadecadienoyl)-glycero-3-phosphoserine

C24H44NO9P (521.2754)

2-(Cyclohexylamino)nicotinic acid

C26H44NNaO6S (521.2787)

H-Ala-Phe-Lys-AMC trifluoroacetate salt

C28H35N5O5 (521.2638)

Tauroursodeoxycholic acid sodium salt

C26H44NNaO6S (521.2787)

Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.

Sodium taurodeoxycholate hydrate

C26H44NNaO6S (521.2787)

Sodium taurochenodeoxycholate

Taurochenodeoxycholic acid sodium salt

C26H44NNaO6S (521.2787)

D005765 - Gastrointestinal Agents > D002756 - Cholagogues and Choleretics D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D000890 - Anti-Infective Agents > D000998 - Antiviral Agents D005765 - Gastrointestinal Agents > D002793 - Cholic Acids Taurochenodeoxycholic acid (12-Deoxycholyltaurine) sodium is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid sodium induces apoptosis and shows obvious anti-inflammatory and immune regulation properties[1][2].

Sodium Taurodeoxycholate

Morphiceptin

C28H35N5O5 (521.2638)

(1r,7ar)-hexahydro-1h-pyrrolizin-1-ylmethyl 3-methoxy-5-(3-methylbut-2-en-1-yl)-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}benzoate

C27H39NO9 (521.2625)

22-(acetyloxy)-5,8-dimethoxy-24-azapentacyclo[14.7.1.1²,⁶.1⁷,¹¹.0²⁰,²⁴]hexacosa-2,4,6(26),7(25),8,10-hexaen-14-yl acetate

C31H39NO6 (521.2777)

n-[6,8a-dihydroxy-2,8-dimethyl-5-(2-methylpropyl)-3-oxo-5h,8h-[1,3]oxazolo[3,2-a]pyrazin-2-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

n-[6,8a-dihydroxy-2,8-dimethyl-5-(2-methylpropyl)-3-oxo-5h,8h-[1,3]oxazolo[3,2-a]pyrazin-2-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C28H35N5O5 (521.2638)

(5r,9r,12ar,13s,15s,15as,16s,18as)-16-benzyl-5,18-dihydroxy-9,15-dimethyl-14-methylidene-2-oxo-5h,6h,7h,8h,9h,10h,12ah,13h,15h,15ah,16h-oxacyclotetradeca[2,3-d]isoindol-13-yl acetate

C31H39NO6 (521.2777)

(5r,9r,12as,13s,15s,15as,16s,18as)-16-benzyl-5,18-dihydroxy-9,15-dimethyl-14-methylidene-2-oxo-5h,6h,7h,8h,9h,10h,12ah,13h,15h,15ah,16h-oxacyclotetradeca[2,3-d]isoindol-13-yl acetate

C31H39NO6 (521.2777)

(1s,3s,7s,10r,11r,12s,16r)-3-[(1e)-1-(2-ethyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione

C28H43NO6S (521.2811)

(4r,7r)-n-[(2r,5s,8s,8as)-6,8a-dihydroxy-2,8-dimethyl-5-(2-methylpropyl)-3-oxo-5h,8h-[1,3]oxazolo[3,2-a]pyrazin-2-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

(4r,7r)-n-[(2r,5s,8s,8as)-6,8a-dihydroxy-2,8-dimethyl-5-(2-methylpropyl)-3-oxo-5h,8h-[1,3]oxazolo[3,2-a]pyrazin-2-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

16-benzyl-5,18-dihydroxy-9,15-dimethyl-14-methylidene-2-oxo-5h,6h,7h,8h,9h,10h,12ah,13h,15h,15ah,16h-oxacyclotetradeca[2,3-d]isoindol-13-yl acetate

C31H39NO6 (521.2777)

(1r,14r,16s,20s,22s)-22-(acetyloxy)-5,8-dimethoxy-24-azapentacyclo[14.7.1.1²,⁶.1⁷,¹¹.0²⁰,²⁴]hexacosa-2,4,6(26),7(25),8,10-hexaen-14-yl acetate

C31H39NO6 (521.2777)

(1s,3s,7s,10r,11s,12s,16r)-3-[(1e)-1-(2-ethyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione

C28H43NO6S (521.2811)